RIP kinase
Receptor-interacting protein kinases; RIPK
Receptor-interacting protein (RIP) kinases are a group of threonine/serine protein kinases with a relatively conserved kinase domain but distinct non-kinase regions. There are seven members of the RIPK family, RIPK1-7, some of which have emerged as critical effectors of immunity to infection with a diverse array of bacterial, viral, and protozoal pathogens.
RIP kinases are cellular signaling molecules that are critical for homeostatic signaling in both communicable and non-communicable disease processes. RIPK1, RIPK2, RIPK3 and RIPK7 have emerged as key mediators of intracellular signal transduction including inflammation, autophagy and programmed cell death, and are thus essential for the early control of many diverse pathogenic organisms.
RIP kinase Isoform Specific Products
All Product Categories
-
RIP kinase Inhibitors
(180)
View all products
-
RIP kinase Activators
(10)
View all products
-
RIP kinase Modulator
(1)
View all products
-
RIP kinase Degraders
(5)
View all products
-
RIP kinase Controls
(2)
View all products
-
RIP kinase Ligands
(4)
View all products
-
Receptor-interacting Serine/Threonine-protein Kinase 3 (RIPK3) Proteins
(3)
View all products
-
RIP kinase Related Products (210)
Related Products (210)
-
Recombinant Proteins (3)
-
Antibodies (2)
-
RIP kinase Isoform Comparison
-
Jak1 RIMTAC-1
0 ImagesCat. No.: HY-187502Jak1 RIMTAC-1 is a JAK1 RIMTAC degrader (a PROTAC-like agent) with a DC50 of 322.8 nM. Jak1 RIMTAC-1 forms a ternary complex with JAK1 and RIPK1, thereby recruiting the VHL E3 ligase complex to ubiquitinate JAK1 via the ubiquitin-proteasome system and mediate its subsequent proteasomal degradation. Jak1 RIMTAC-1 does not alter JAK1 mRNA levels (pink: Jak1 ligand-1 (HY-187503); blue: RIPK1-ligand-4 (HY-187391); black: Linker (HY-B0704)).
-
BRD4 RIMTAC-1
0 ImagesCat. No.: HY-187390BRD4 RIMTAC-1 is a BRD4 PROTAC degrader based on the RIPK1-mediated targeted chimera (RIMTAC) technology. It hijacks the endogenous RIPK1-VHL complex via the RIPK1 inhibitor moiety to indirectly recruit the VHL E3 ligase, forming a BRD4-Compound 10-RIPK1-VHL quaternary complex, and degrades BRD4 through the ubiquitin-proteasome system (UPS). BRD4 RIMTAC-1 exhibits selectivity over other BET proteins, induces concentration- and time-dependent, reversible post-translational degradation of BRD4 without altering the target mRNA level. BRD4 RIMTAC-1 potently induces endogenous BRD4 degradation in RAW264.7 and HEK-293T cells, with DC50 values of 179.1 nM and 54.12 nM, respectively. BRD4 RIMTAC-1 can be used for the research of cancer and inflammation-related diseases.
-
RIP2 Kinase Inhibitor 4
0 ImagesCat. No.: HY-136010CAS No.: 2126803-41-4
-
Necroptosis-IN-5
0 ImagesCat. No.: HY-161911Necroptosis-IN-5 (Compound 26) is an orally active necroptosis inhibitor. Necroptosis-IN-5 also exhibits potent inhibitory activity against receptor-interacting protein kinase 1 (RIPK1). Necroptosis-IN-5 can be used to study necroptosis-related inflammatory diseases, neurodegenerative diseases, and cancers.
-
RIPK1-IN-8
0 ImagesCat. No.: HY-143726CAS No.: 2319663-07-3RIPK1-IN-8 (example 16), an aminoimidazopyridine, is a potent and selective RIPK1 inhibitor with an IC50 of 4 nM. RIPK1-IN-8 has the potential for inflammatory diseases research.
-
RIPK3-IN-2
0 ImagesCat. No.: HY-148052CAS No.: 2665669-32-7RIPK3-IN-2 is a RIP3 inhibitor. RIPK3-IN-2 can be used in diseases caused by or associate with activated necrotic pathways research.
-
RIPK1-IN-35
0 ImagesCat. No.: HY-178762SCAS No.: 3103886-96-7RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC50 of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis.
-
RIPK1-IN-32
0 ImagesCat. No.: HY-175007RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis.
-
GSK-872 (Standard)
0 ImagesCat. No.: HY-101872RCAS No.: 1346546-69-7GSK-872 (Standard) is the analytical standard of GSK-872 (HY-101872). This product is intended for research and analytical applications. GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.
-
GSK963 (Standard)
0 ImagesCat. No.: HY-103028ARCAS No.: 2049868-46-2GSK963 (Standard) is the analytical standard of GSK963 (HY-103028A). This product is intended for research and analytical applications. GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC50 of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro.
-
MLKL-IN-4
0 ImagesCat. No.: HY-151542CAS No.: 3031406-17-1MLKL-IN-4 (compound 56) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC50 of 82 nM. MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Ligustroflavone (Standard)
0 ImagesCat. No.: HY-N0546RCAS No.: 260413-62-5Synonyms: Nuezhenoside (Standard)Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
-
GSK840 (Standard)
0 ImagesSynonyms: GSK'840 (Standard)GSK840 (Standard) is the analytical standard of GSK840 (HY-104021). This product is intended for research and analytical applications. GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM.
-
GSK2982772 (Standard)
0 ImagesCat. No.: HY-101760RCAS No.: 1622848-92-3GSK2982772 (Standard) is the analytical standard of GSK2982772 (HY-101760). This product is intended for research and analytical applications. GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively.
-
RIP1 Kinase inhibitor 1 (Standard)
0 ImagesCat. No.: HY-111409RCAS No.: 2095515-38-9RIP1 Kinase inhibitor 1 (Standard) is the analytical standard of RIP1 Kinase inhibitor 1 (HY-111409). This product is intended for research and analytical applications. RIP1 Kinase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating RIP1 Kinase inhibitor (pKi=9.04).
-
Necrostatin 2 racemate (Standard)
0 ImagesSynonyms: Necrostatin 1S (Standard); Nec-1S (Standard); 7-Cl-O-Nec1 (Standard)Necrostatin 2 (racemate) (Standard) is the analytical standard of Necrostatin 2 (racemate). This product is intended for research and analytical applications. Necrostatin 2 racemate (Nec-1S), the Necrostatin-1 (HY-15760) stable, is a potent and specific RIPK1 inhibitor lacking the IDO-targeting effect.
